Alamar Biosciences (NASDAQ:ALMR) Coverage Initiated by Analysts at Bank of America

Equities researchers at Bank of America initiated coverage on shares of Alamar Biosciences (NASDAQ:ALMR) in a report issued on Tuesday. The firm set a “neutral” rating and a $27.00 price target on the stock. Bank of America‘s target price indicates a potential upside of 13.07% from the company’s current price.

A number of other research firms have also issued reports on ALMR. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Stifel Nicolaus initiated coverage on shares of Alamar Biosciences in a report on Tuesday. They set a “buy” rating and a $28.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Alamar Biosciences in a report on Tuesday. They set an “overweight” rating and a $30.00 target price for the company. TD Cowen initiated coverage on shares of Alamar Biosciences in a report on Tuesday. They set a “buy” rating and a $30.00 target price for the company. Finally, Leerink Partners began coverage on shares of Alamar Biosciences in a report on Tuesday. They set an “outperform” rating and a $35.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Alamar Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Alamar Biosciences Price Performance

ALMR stock opened at $23.88 on Tuesday. Alamar Biosciences has a 52 week low of $21.50 and a 52 week high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The business had revenue of $26.04 million for the quarter.

Insider Buying and Selling at Alamar Biosciences

In related news, Director Nicholas Naclerio purchased 235,294 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the director owned 507,076 shares in the company, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the insider owned 507,076 shares in the company, valued at $8,620,292. This represents a 86.57% increase in their position. The SEC filing for this purchase provides additional information.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.